A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats

Behavioural Pharmacology

Volumn 23, Issue 2, 2012, Pages 162-170

  Morani, Aashish S ^a   Schenk, Susan ^a   Prisinzano, Thomas E ^b   Kivell, Bronwyn Maree ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

behavioral sensitization; conditioned taste aversion; depression; forced swim test; kappa opioid agonist; rat; salvinorin A

Indexed keywords

COCAINE; KAPPA OPIATE RECEPTOR AGONIST; SALVINORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; BEHAVIOR; CLINICAL EVALUATION; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; HUMAN; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; RAT; SENSITIZATION; SWIMMING;

ANIMALS; AVOIDANCE LEARNING; CENTRAL NERVOUS SYSTEM SENSITIZATION; COCAINE; CONDITIONING (PSYCHOLOGY); DITERPENES, CLERODANE; IMMOBILITY RESPONSE, TONIC; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; STEREOTYPED BEHAVIOR;

EID: 84858702496     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283512c1e     Document Type: Article

References (83)

1. Baker L, Panos J, Killinger B, Peet M, Bell L, Haliw L, et al. (2009). Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69593 and U50488 in rats. Psychopharmacology 203:203-211.
2. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993). Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264:489-495. (Pubitemid 23309241)
3. Beninger R, Herz R (1986). Pimozide blocks establishment but not expression of cocaine-produced environment-specific conditioning. Life Sci 38: 1425-1431. (Pubitemid 16033496)
4. Braida D, Limonta V, Pegorini S, Zani A, Guerini-Rocco C, Gori E, et al. (2007). Hallucinatory and rewarding effect of salvinorin A in zebrafish: k-opioid and CB-1 cannabinoid receptor involvement. Psychopharmacology 190:441-448. (Pubitemid 46204461)
5. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, et al. (2008). Involvement of [kappa]-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry 63:286-292.
6. Braida D, Capurro V, Zani A, Rubino T, ViganòD, Parolaro D, et al. (2009). Potential anxiolytic-and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum in rodents. Br J Pharmacol 157: 844-853.
7. Bruijnzeel AW (2009). Kappa-opioid receptor signaling and brain reward function. Brain Res Rev 62:127-146.
8. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ (2007). Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 320:300-306. (Pubitemid 46025744)
9. Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ (2009). Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328:588-597.
10. Cadoni C, Solinas M, Di Chiara G (2000). Psychostimulant sensitization: differential changes in accumbal shell and core dopamine. Eur J Pharmacol 388:69-76. (Pubitemid 30066438)
11. Carlezon WA, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, et al. (1998). Regulation of Cocaine Reward by CREB. Science 282:2272-2275. (Pubitemid 29004079)
12. Carlezon WA Jr, Bé guin C, DiNieri JA, Baumann MH, Richards MR Todtenkopf MS, et al. (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447. (Pubitemid 41832624)
13. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA Jr (2008). Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacol 33:2676-2687.
14. Chartoff EH, Papadopoulou M, MacDonald ML, Parsegian A, Potter D, Konradi C, et al. (2009). Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 75: 704-712.
15. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS (2005). Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25:5029-5037. (Pubitemid 40712846)
16. Collins S, Gerdes RM, D'Addario C, Izenwasser S (2001). Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. Behav Pharmacol 12:237-245. (Pubitemid 32730505)
17. Detke M, Rickels M, Lucki I (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72.
18. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
19. Ebner S, Roitman M, Potter D, Rachlin A, Chartoff E (2010). Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology 210:241-252.
20. Fantegrossi W, Kugle KM, Valdes LJ III, Koreeda M, Woods JH (2005). Kappaopioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16:627-633. (Pubitemid 41682197)
21. Fenu S, Rivas E, Di Chiara G (2005). Differential role of dopamine in drug-and lithium-conditioned saccharin avoidance. Physiol Behav 85:37-43. (Pubitemid 40753557)
22. Gehrke B, Chefer V, Shippenberg TS (2008). Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology 197:509-517.
23. Glick S, Maisonneuve I, Raucci J, Archer S (1995). Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147-152.
24. Griffin OH, Miller BL, Khey DN (2008). Legally high? Legal considerations of Salvia divinorum. J Psychoactive Drugs 40:183-191.
25. Heidbreder CA, Goldberg SR, Shippenberg TS (1993). The kappa-opioid receptor agonist U69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616:335-338. (Pubitemid 23200066)
26. Heidbreder CA, Babovic-Vuksanovic D, Shoaib M, Shippenberg TS (1995). Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275:150-163.
27. Heidbreder CA, Thompson AC, Shippenberg TS (1996). Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther 278:490-502. (Pubitemid 27167011)
28. Hooker J, Patel V, Kothari S, Schiffer W (2009). Metabolic changes in the rodent brain after acute administration of salvinorin A. Mol Imaging Biol 11:137-143.
29. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS (2008). Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. NeuroImage 41:1044-1050.
30. Hooks S, Duffy P, Striplin C, Kalivas P (1994). Behavioral and neurochemical sensitization following cocaine self-administration. Psychopharmacology 115:265-272. (Pubitemid 24207792)
31. John TF, French LG, Erlichman JS (2006). The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol 545:129-133.
32. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150-155.
33. Kalivas PW, Duffy P (1990). Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 5:48-58. (Pubitemid 20110621)
34. Kalivas PW, Duffy P (1993a). Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 13:266-275. (Pubitemid 23028742)
35. Kalivas PW, Duffy P (1993b). Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci 13:276-284. (Pubitemid 23028743)
36. Kalivas PW, Pierce RC, Cornish J, Sorg BA (1998). A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 12:49-53. (Pubitemid 28142999)
37. Kelly BC (2011). Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 43:46-54.
38. Kuzmin AV, Semenova S, Gerrits MA, Zvartau EE, Van Ree JM (1997). Kappaopioid receptor agonist U50488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur J Pharmacol 321: 265-271. (Pubitemid 27106827)
39. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC, et al. (2003). Antidepressant-like effects of k-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330. (Pubitemid 36373867)
40. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ (2006). Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83:109-113.
41. Mello NK, Negus SS (2000). Interactions between Kappa opioid agonists and cocaine: preclinical studies. Ann NY Acad Sci 909:104-132. (Pubitemid 30462035)
42. Morani AS, Kivell B, Prisinzano TE, Schenk S (2009). Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaineinduced drug-seeking in rats. Pharmacol Biochem Behav 94:244-249.
43. Mucha RF, Herz A (1985). Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274-280. (Pubitemid 15064950)
44. Mysels D, Sullivan MA (2009). The kappa-opiate receptor impacts the pathophysiology and behavior of substance use. Am J Addict 18:272-276.
45. Nestler EJ, Carlezon WA (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159. (Pubitemid 44192421)
46. Phillips A, Di Ciano P (1996). Behavioral sensitization is induced by intravenous self-administration of cocaine by rats. Psychopharmacology 124:279-281. (Pubitemid 26130539)
47. Porsolt R (1979). Animal model of depression. Biomedicine 30:139-140. (Pubitemid 9235293)
48. Post R, Lockfeldk A, Squjllac M, Contel N (1981). Drug-environment interaction: context dependency of cocaine-induced behavioral sensitization. Life Sci 28:755-760. (Pubitemid 11097487)
49. Post R, Weiss SR, Pert A, Uhde T (1987). Chronic cocaine administration: sensitization and kindling effects. In: Fisher S, Raskin A, Uhlenhuth EH, editors. Cocaine: clinical and biobehavioral aspects. New York: Oxford University Press; pp. 109-173.
50. Prevatt-Smith KM, Prisinzano TE (2010). New therapeutic potential for psychoactive natural products. Nat Prod Rep 27:23-31.
51. Prisinzano T, Tidgewell K, Harding WW (2005). Kappa opioids as potential treatments for stimulant dependence. AAPS J 7:E592-E599.
52. Reith M, Li MY, Yan QS (1997). Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology 134:309-317. (Pubitemid 27520985)
53. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentivesensitization theory of addiction. Brain Res Rev 18:247-291. (Pubitemid 23219500)
54. Robinson TE, Berridge KC (2001). Incentive-sensitization and addiction. Addiction 96:103-114. (Pubitemid 32099343)
55. Robinson TE, Berridge KC (2003). Addiction. Ann Rev Psychol 54:25-53. (Pubitemid 37417487)
56. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, et al. (2002). Salvinorin A: a potent naturally occurring non-nitrogenous kappaopioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939. (Pubitemid 34994502)
57. Schenk S, Hunt T, Klukowski G, Amit Z (1987). Isolation housing decreases the effectiveness of morphine in the conditioned taste aversion paradigm. Psychopharmacology (Berl) 92:48-51. (Pubitemid 17063661)
58. Schenk S, Partridge B, Shippenberg TS (1999). U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaineproduced drug-seeking. Psychopharmacology 144:339-346. (Pubitemid 29307258)
59. Schenk S, Partridge B, Shippenberg TS (2000). Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist U69593. Psychopharmacology 151:85-90. (Pubitemid 30639844)
60. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, et al. (2005). Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58:208-210. (Pubitemid 41443741)
61. Shippenberg TS, Heidbreder C (1995). Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J Pharmacol Exp Ther 273:808-815.
62. Shippenberg TS, Herz A (1986). Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75:563-566.
63. Shippenberg TS, LeFevour A, Heidbreder C (1996). Kappa-opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276:545-554.
64. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001). Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann NY Acad Sci 937:50-73. (Pubitemid 32613879)
65. Shippenberg TS, Zapata A, Chefer VI (2007). Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116:306-321. (Pubitemid 47454747)
66. Smith JC, Morris DD, Hendricks J (1964). Conditioned aversion to saccharin solution with dose rates of X-rays as the unconditioned stimulus. Radiat Res 22:507-510.
67. Steketee J (2005). Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol 17:69-86. (Pubitemid 44174001)
68. Sun W, Xue Y, Huang Z, Steketee J (2010). Regulation of cocaine-reinstated drug-seeking behavior by k-opioid receptors in the ventral tegmental area of rats. Psychopharmacology 210:179-188.
69. Tao R, Auerbach SB (2005). Mu-opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res 1049:70-79. (Pubitemid 40814576)
70. Todtenkopf M, Marcus J, Portoghese P, Carlezon WA Jr (2004). Effects of kappaopioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172:463-470. (Pubitemid 38650984)
71. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr (2008). The kappa-opioid agonist U69593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64:982-988.
72. Ushijima MA, Carino A, Horita (1995). Involvement of D1 and D2 dopamine systems in the behavioral effects of cocaine in rats. Pharmacol Biochem Behav 52:737-741.
73. Valdé s LJ III (1994). Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. J Psychoactive Drugs 26:277-283.
74. Valdés LJ III, Díaz JL, Paul AG (1983). Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M. ). J Ethnopharmacol 7:287-312. (Pubitemid 13078303)
75. Vanderschuren LJ, Pierce RC (2010). Sensitization processes in drug addiction. Curr Top Behav Neurosci 3:179-195.
76. Vanderschuren LJ, Schoffelmeer AN, Wardeh G, De Vries TJ (2000). Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine. Psychopharmacology 150: 35-44. (Pubitemid 30350811)
77. Vortherms TA, Roth BL (2006). Salvinorin A: from natural product to human therapeutics. Mol Interv 6:257-265. (Pubitemid 44556046)
78. Wadenberg M (2003). A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev 9:187-198. (Pubitemid 36903891)
79. Walsh S, Strain E, Abreu M, Bigelow G (2001). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151-162. (Pubitemid 32802126)
80. Willmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH (2007). The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology 53: 481-486. (Pubitemid 47284181)
81. Yan F, Roth BL (2004). Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci 75:2615-2619. (Pubitemid 39215054)
82. Yilmaz B, Sandal S, Canpolat S, Kutlu, Kelestimur H (2006). Kappa opioid modulation of serotonergic neurotransmission in the hypothalamus, hippocampus and striatum in the male rat. Firat T{p Dergisi 11:12-15.
83. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology 179: 551-558. (Pubitemid 40674756)